Chlorambucil
- Generic Name
- Chlorambucil
- Brand Names
- Leukeran
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19Cl2NO2
- CAS Number
- 305-03-3
- Unique Ingredient Identifier
- 18D0SL7309
- Background
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
- Indication
For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Hodgkins Disease (HD), Indolent Lymphoma, Lymphoma, Lymphoma, Diffuse, MALT Lymphoma, Mantle Cell Lymphoma (MCL), Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Waldenström's Macroglobulinemia (WM), Giant follicular lymphoma
- Associated Therapies
- -
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT02053610
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
- Conditions
- Interventions
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT01998880
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 57
- Registration Number
- NCT01980875
- Locations
- 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
🇫🇷Centre Hospitalier de Perpignan, Perpignan Cedex 9, France
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 979
- Registration Number
- NCT01905943
- Locations
- 🇧🇷
Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil
🇧🇷Hospital de Cancer de Barretos, Barretos, SP, Brazil
🇧🇷Hospital Amaral Carvalho, Jau, SP, Brazil
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01868893
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Cancer Center of Central Conn., Southington, Connecticut, United States
🇺🇸Peachtree Hematology & Oncology Consultants, Pc, Atlanta, Georgia, United States
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 112
- Registration Number
- NCT01808599
- Locations
- 🇫🇷
Dijon CHU Hopital le Bocage, Dijon, France
🇫🇷Clermont Ferrand CHU Estaing, Estaing, France
🇮🇹AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 269
- Registration Number
- NCT01722487
- Locations
- 🇺🇸
Site Reference ID/Investigator #125, Atlanta, Georgia, United States
🇺🇸Site Reference ID/Investigator #050, Pittsburgh, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator #032, Houston, Texas, United States
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 670
- Registration Number
- NCT01678430
- Locations
- 🇬🇧
Derriford Hospital, Plymouth, Devon, United Kingdom
🇬🇧Torbay Hospital, Torquay, Devon, United Kingdom
🇬🇧Dorset County Hospital, Dorchester, Dorset, United Kingdom
Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
- Target Recruit Count
- 96
- Registration Number
- NCT01657955
- Locations
- 🇨🇳
Hematologic hospital of Chinese academy of medical sciences, Tianjin, China
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
- Conditions
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT01283386
- Locations
- 🇷🇺
City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation
🇷🇺Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation
🇷🇺The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.